Children who have been diagnosed with SMA Type 1

If they are well enough, these children may be able to have any one of the three treatments.

Zolgensma

Children must weigh less than 21 kg. As risks increase with weight, children over 13.5 kgs should only be treated in specific circumstances. All children must also have  a number of blood tests to make sure it is safe for them to have this treatment. These include how well their liver, kidney and heart are working. They also must have an AAV9 antibody test (see ‘How do the treatments work’ below)

Children who have been diagnosed with SMA Type 2 or 3

If they are well enough, these children may be able to have Spinraza or Risdiplam.

These children may be identified in one of two ways:

• If the parents already have a child who has SMA – during the pregnancy or at birth
• Through the Oxford-Thames Valley – Wessex SMA newborn screening research pilot.

Children who have between 1 and 3 copies of the SMN2 gene

These children may be able to have any one of the three treatments. A number of blood tests have to be done to make sure it is safe for them to have Zolgensma. These include how well their liver, kidney and heart are working. They also must have an AAV9 antibody test (see ‘How do the treatments work’ below).

Children who have 4 copies of the SMN2 gene

These children may be able to have Spinraza or Risdiplam.

People with SMA do not have enough of a protein called ‘survival motor neuron’ (SMN) protein. This protein is essential for the nerve cells, known as motor neurons that help control muscles. Motor neurons are found in the brain and spinal cord, and they make contact with muscles.

The SMN protein is made in our cells from two genes, SMN1 and SMN2. People who have SMA have:

• two ‘altered’ copies of the SMN1 gene. These are unable to produce enough SMN protein to have healthy lower motor neurons.
• a number of copies of the SMN2 gene. This is often called the back-up gene. It mostly produces a short SMN protein that does not work as well as a full-length protein.

All three treatments increase the amount of SMN protein found in cells throughout the body. They do this in different ways.

Spinraza

This is a small piece of genetic material (a synthetic antisense oligonucleotide). It targets the ‘back-up’ SMN2 gene. It makes the gene produce more usable full-length SMN protein.

Zolgensma

This is a gene therapy. It delivers a healthy copy of the SMN1 gene to motor neurons. So that the gene can reach the intended cells, it is packaged inside an inactive shell of a virus called AAV9 (adeno-associated virus 9) in order to  transport it to the target cells.

Risdiplam

This is a small molecule drug. It targets the ‘back-up’ SMN2 gene. It makes the gene produce more usable, full-length SMN protein.

None of the treatments is a cure. This is because:

• Timing is critical. Treatments can quickly boost SMN protein after they are given. But, by then, some damage may be irreversible. This may happen even before a baby is born.
• It is unknown if the treatments will have lasting effects. They are all so new.

They are often called disease-modifying treatments.

Spinraza

This is given by lumbar puncture. A needle is inserted through the skin into the space between the back bones of the spine (vertebrae) into the fluid that flows in and around the brain and spinal cord (cerebrospinal fluid  -CSF). Doctors usually use a local anaesthetic such as ‘numbing cream’ when they do this. If a sedative or general anaesthetic is needed, the doctor will decide if this is safe for the child or if a different treatment should be considered.

The total length of time the procedure takes will vary. The injection itself takes between one and three minutes.

‘Loading doses’ are given to get the level of the drug to an effective concentration within the CSF. These are:

• On the first day of treatment, day 0
• Then around day 14, day 28 and day 63
• There should always be at least 14 days between doses.

Once the loading doses have all been delivered, there are then maintenance doses every 4 months to maintain the drug concentration level in the CSF.

Zolgensma

This is a single one-time treatment injected into the bloodstream (intravenously). A small flexible tube (cannula) is placed into a vein in the arm or leg using a needle. The needle is then removed leaving the cannula in place for the infusion. Sometimes, for safety reasons, two cannulas are inserted. It takes about 60 minutes to deliver the treatment.

Families are given advice about what to do before and after treatment. This includes limiting contacts to help prevent infections.

All children are treated with corticosteroids before and after the treatment, to reduce side effects. Corticosteroids are given for at least three months, usually by mouth. After that time, the treating doctor assesses when and how corticosteroids can be stopped. It is not safe to suddenly stop steroids.

Risdiplam

This is given as a liquid at home. It is taken daily after a meal, at approximately the same time each day. It is given by mouth (orally) or feeding tube, using the syringe that comes with it.  It is provided in a bottle in a box that must be kept in the fridge. It comes with instructions about how long it is safe to keep it out of a fridge and what is the allowed maximum temperature.

All three treatments reach the motor neurons to treat SMA.

All three treatments reach other types of cells. The extent of this, and any potential benefits, are unknown.

Your clinical team will discuss the possible risks and benefits of each treatment with you.

You can read more on this topic if you follow the links at the top of this page. Each treatment also has a detailed Patient Information Leaflet:

There are no clinical trials or studies that directly compare the effects of these treatments.

In these trials, all three treatments have been consistently shown to have an acceptable safety profile and to be well-tolerated.

When compared to no treatment, all three treatments have led to clinically meaningful improvements in muscle function.

The long-term outcomes and the specific outcomes for any individual child are uncertain.

Your child’s clinical team will know about the clinical trials for each treatment. They will have ‘real world’ information that is being collected and discussed all the time.